Revolution Medicines (RVMD) just crossed a major regulatory hurdle, with the FDA approving Rasonque for metastatic pancreatic adenocarcinoma after Phase 3 data showed an overall survival benefit across all tested RAS subgroups and treatment settings.
That regulatory win comes on top of a powerful price run, with Revolution Medicines posting a year to date share price return of 145.8% and a one year total shareholder return of 231.62%. Momentum has cooled recently, with the 30 day share price return down 6.01% and the 90 day share price return down 1.56%, even as the stock gained 3.22% in the last session to close at US$194.23 ahead of its upcoming Q3 2026 update and recent ESMO data presentations.
Scan beyond Revolution Medicines and compare this move with a curated group of oncology and high-science biotechs screened for momentum and fundamentals using the 19 high quality undiscovered gems.
Revolution Medicines now trades at a steep discount to both analyst targets and intrinsic value estimates after a sharp run. Is that a pricing error or a rational cushion for a business still reporting heavy losses and no revenue?
Most Popular Narrative: 25% Undervalued
Revolution Medicines last closed at $194.23, while the most followed narrative pegs fair value at about $257.47 using a 7.54% discount rate and aggressive long term growth and profitability assumptions.
The move toward targeted oncology treatments for high unmet need tumors such as pancreatic, lung and colorectal cancer aligns with the company’s RAS(ON) portfolio. This could influence long term revenue growth if multiple registrational programs convert to approved therapies.
Eight ongoing or planned Phase III registrational trials and clinical experience in more than 2,500 patients create multiple data points over the next few years. These developments could change how investors view the durability and scale of the pipeline, with potential implications for future revenue visibility and earnings power.
See why 19 investors see Revolution Medicines as 25% undervalued.
Result: Fair Value of $257.47 (UNDERVALUED)
Still, the story can break if heavy operating spend keeps net losses elevated for longer than expected or if key RAS(ON) trials fail to convert into approvals.
Find out about the key risks to this Revolution Medicines narrative.
Next Steps
Mixed messages in the Revolution Medicines story so far. If you want a sharper view and to act before sentiment swings again, start with the headline positives and pressure points in the 3 key rewards and 2 important warning signs.
Looking for more investment ideas beyond Revolution Medicines?
If Revolution Medicines has your attention, do not stop here. Use the Simply Wall Street Screener to line up your next potential opportunities across different styles.
- Target value first and hunt for mispriced quality by running the 34 high quality undervalued stocks.
- Prioritise resilience and focus on financial strength with the list of solid balance sheet and fundamentals (24 results).
- Dial down risk and concentrate on stability by filtering through the 30 resilient stocks with low risk scores.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com